XKRX237690
Market cap1.11bUSD
Dec 24, Last price
86,100.00KRW
1D
0.94%
1Q
-16.65%
Jan 2017
91.97%
IPO
95.68%
Name
ST Pharm Co Ltd
Chart & Performance
P/E
82.70
P/S
5.68
EPS
1,041.07
Div Yield, %
0.58%
Shrs. gr., 5y
0.16%
Rev. gr., 5y
23.87%
Revenues
284.99b
+14.31%
Net income
19.58b
+8.78%
CFO
1.30b
-82.59%
Dividend
Dec 27, 2023500 KRW/sh
Earnings
Jan 30, 2025
Profile
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 284,991,652 14.31% | 249,321,678 50.52% | 165,641,947 33.47% | ||||||
Cost of revenue | 218,988,478 | 200,391,422 | 135,205,241 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 66,003,174 | 48,930,256 | 30,436,706 | ||||||
NOPBT Margin | 23.16% | 19.63% | 18.37% | ||||||
Operating Taxes | 5,830,842 | 1,721,312 | (2,117,184) | ||||||
Tax Rate | 8.83% | 3.52% | |||||||
NOPAT | 60,172,332 | 47,208,944 | 32,553,890 | ||||||
Net income | 19,581,190 8.78% | 18,000,015 443.46% | 3,312,125 -127.27% | ||||||
Dividends | (9,404,388) | (9,404,388) | |||||||
Dividend yield | 0.74% | 0.57% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 30,250,033 | 115,333,066 | 15,587,237 | ||||||
Long-term debt | 165,013,048 | 19,187,686 | 91,930,129 | ||||||
Deferred revenue | 23,731,252 | 24,584,342 | 23,746,826 | ||||||
Other long-term liabilities | 19,222,230 | 6,686,170 | (18,986,871) | ||||||
Net debt | 94,437,677 | 72,828,052 | 1,037,442 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 1,298,383 | 7,456,125 | 7,648,754 | ||||||
CAPEX | (43,244,230) | (60,663,455) | (51,918,202) | ||||||
Cash from investing activities | (82,388,093) | (7,078,965) | (7,711,590) | ||||||
Cash from financing activities | 82,732,434 | 11,737,715 | (816,423) | ||||||
FCF | (21,565,756) | (59,283,006) | (16,583,231) | ||||||
| Balance | |||||||||
Cash | 90,097,156 | 50,201,066 | 93,216,238 | ||||||
Long term investments | 10,728,248 | 11,491,634 | 13,263,685 | ||||||
Excess cash | 86,575,822 | 49,226,616 | 98,197,826 | ||||||
Stockholders' equity | 160,965,937 | 156,726,812 | 141,689,225 | ||||||
Invested Capital | 533,009,609 | 455,154,850 | 339,236,924 | ||||||
ROIC | 12.18% | 11.89% | 10.19% | ||||||
ROCE | 10.61% | 9.58% | 6.85% | ||||||
| EV | |||||||||
Common stock shares outstanding | 18,809 | 18,809 | 18,660 | ||||||
Price | 67,800.00 -22.60% | 87,600.00 -37.07% | 139,200.00 34.10% | ||||||
Market cap | 1,275,234,945 -22.60% | 1,647,648,690 -36.57% | 2,597,497,891 34.13% | ||||||
EV | 1,372,028,682 | 1,723,947,901 | 2,601,593,782 | ||||||
EBITDA | 89,029,873 | 66,530,513 | 44,850,971 | ||||||
EV/EBITDA | 15.41 | 25.91 | 58.01 | ||||||
Interest | 6,105,605 | 2,867,836 | 5,157,415 | ||||||
Interest/NOPBT | 9.25% | 5.86% | 16.94% | ||||||